$DWTX Cashflow Statement | Understand Stock

$DWTX

$1.24 +$0.08 (6.9%) Close

$DWTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on foreign exchange
Loss on fixed asset disposal
Amortization of loan costs
Depreciation
Reduction in carrying amount of right-of-use asset
Loss on debt conversion with related party
Acquisition of license for research and development
Non-cash transaction costs
Deferred tax expense (benefit)
Share-based compensation expense
Changes in operating assets and liabilities:
Increase in prepaid expenses and other current assets
(Decrease) increase in accounts payable
Decrease in accrued expenses
Decrease in accrued salaries
Increase (decrease) in accrued expenses and other liabilities

Net cash used in operating activities
Cash flows from investing activities
Cash acquired through the acquisition of Pharmagesic
Net cash provided by investing activities
Cash flows from financing activities
Proceeds from the exercise of warrants
Proceeds from public offering of common stock, net of offering costs
Proceeds from loan with related party, net of fees
Payout of fractional shares with reverse stock split
Cash payment of issuance costs
Net cash provided by financing activities

Net (decrease) increase in cash
Cash and cash equivalents, beginning of period
Effect of foreign currency translation on cash and cash equivalents
Cash and cash equivalents, end of period
Supplemental disclosure of non-cash financing and investing activities:
Issuance costs included in accounts payable and accrued expenses
Conversion of accrued interest on debt with related party into Series A-1 Non-Voting Convertible Preferred Stock
Conversion of Series A Non-Voting Convertible Preferred Stock from temporary equity to permanent equity
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock
Temporary Equity, Accrual of paid-in-kind dividends on Serise A Non-Voting Convertible Preferred Stock
Reduction in equity for shares surrendered in cashless warrant exercises
Preferred stock issued in connection with License Agreement
Common stock issued in connection with License Agreement
Conversion of preferred stock into common stock
Preferred stock issued in connection with acquisition of Pharmagesic
Common stock issued in connection with acquisition of Pharmagesic

Comments